Konrad Rejdak, M.D. – FDA Inspection, May 19, 2023

Record Details

This FDA Inspection record concerns Konrad Rejdak, M.D., with an inspection on May 19, 2023, issued by the Center for Biologics Evaluation and Research, covering biologics.

Company: Konrad Rejdak, M.D.
Inspection Date: May 19, 2023
Product Type: Biologics
Office: Center for Biologics Evaluation and Research
Person: Alanna L. Mussawwir Bias

View Company Profile

ID · 11a37c52-0af4-4ca9-ae20-1862fc12e96e

Inspection Facts

Official Action Indicated (OAI)

Significant objectionable conditions were found and regulatory or administrative action is recommended.

Inspection number: 1206061
FDA center: Biologics
Project area: Bioresearch Monitoring
Outcome: Form 483 issued

FDA Citations

21 CFR 312.62(b)Case history records- inadequate or inadequate
21 CFR 312.62(b)Case history records- inadequate or inadequate

Full citation text and observation details available on the Dashboard.

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Konrad Rejdak, M.D.

FDA Inspection

Konrad Rejdak, M.D.May 19, 2023